Abstract
The diabetic foot remains a major cause of morbidity worldwide. Ischaemia due to peripheral arterial disease significantly contributes to its pathogenesis and natural history. Increased revascularisation has been decisive in improving outcomes. However, there is still a need for further improvement. Advances in the treatment of ischaemia in the diabetic foot include therapeutic angiogenesis, stem cell therapy and miscellaneous modalities. Angiogenesis has yielded encouraging results in the treatment of peripheral arterial disease, but it has not been studied enough in patients with diabetes. Choice of patients, reliable study endpoints, as well as safety of growth factors in diabetic patients, who have an excess risk of widespread vascular disease, need to be addressed more convincingly. Similar improvement is required in the other emerging therapeutic options. From a practical point of view, until novel modalities are available, increased vigilance and prompt aggressive revascularisation are indispensable to reduce the rate of amputations.
Keywords: Angiogenesis, diabetic foot, ischaemia, peripheral arterial disease
Current Vascular Pharmacology
Title: Advances in Treating the Ischaemic Diabetic Foot
Volume: 6 Issue: 1
Author(s): Nikolaos Papanas and Efstratios Maltezos
Affiliation:
Keywords: Angiogenesis, diabetic foot, ischaemia, peripheral arterial disease
Abstract: The diabetic foot remains a major cause of morbidity worldwide. Ischaemia due to peripheral arterial disease significantly contributes to its pathogenesis and natural history. Increased revascularisation has been decisive in improving outcomes. However, there is still a need for further improvement. Advances in the treatment of ischaemia in the diabetic foot include therapeutic angiogenesis, stem cell therapy and miscellaneous modalities. Angiogenesis has yielded encouraging results in the treatment of peripheral arterial disease, but it has not been studied enough in patients with diabetes. Choice of patients, reliable study endpoints, as well as safety of growth factors in diabetic patients, who have an excess risk of widespread vascular disease, need to be addressed more convincingly. Similar improvement is required in the other emerging therapeutic options. From a practical point of view, until novel modalities are available, increased vigilance and prompt aggressive revascularisation are indispensable to reduce the rate of amputations.
Export Options
About this article
Cite this article as:
Papanas Nikolaos and Maltezos Efstratios, Advances in Treating the Ischaemic Diabetic Foot, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331330
DOI https://dx.doi.org/10.2174/157016108783331330 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia
Current Neurovascular Research Renal Artery Stenosis: A Unique Disease or a Broad Spectrum of Different Diseases?
Current Hypertension Reviews Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years
Current Vascular Pharmacology Vascular Factors and Mitochondrial Dysfunction: a Central Role in the Pathogenesis of Alzheimer’s Disease
Current Neurovascular Research The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Is the Use of Autologous Platelet-Rich Plasma Gels in Gynecologic, Cardiac, and General, Reconstructive Surgery Beneficial?
Current Pharmaceutical Biotechnology Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Alternative Routes for the Formation of Immunochemically Distinct Advanced Glycation End-products In Vivo
Current Molecular Medicine Meet Our Editorial Board Member
Current Topics in Medicinal Chemistry EDITORIAL [Hot Topic: Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Ophthalmic Conditions (Guest Editor: Michael W. Stewart)]
Current Drug Therapy Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets